✨ Your Portfolio is fetched and updated from zerodha.
Mid Pharmaceuticals

Aurobindo Pharma Ltd.

AUROPHARMA

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹68,340 Cr.
P/E
19.97

Aurobindo Pharma Ltd.

  • Aurobindo Pharma
  • Alkem Laboratories
  • Abbott India
  • TJI Pharma

FAQs on Aurobindo Pharma Ltd. Shareprice

Aurobindo Pharma has given lower returns compared to its competitors.
Aurobindo Pharma has grown at ~7.58% over the last 2yrs while peers have grown at a median rate of 20.33%

Yes, Aurobindo Pharma is expensive.
Latest PE of Aurobindo Pharma is 20.66, while 3 year average PE is 17.69.
Also latest EV/EBITDA of Aurobindo Pharma is 10.42 while 3yr average is 10.23.

View FAQ's On Business

Growth Table

  • Aurobindo Pharma Ltd.
  • Alkem Laboratories
  • Abbott India

Balance Sheet

  • Aurobindo Pharma Ltd.
  • Alkem Laboratories
  • Abbott India

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Aurobindo Pharma Ltd.
  • Alkem Laboratories
  • Abbott India

Cash Flow

  • Aurobindo Pharma Ltd.
  • Alkem Laboratories
  • Abbott India

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Aurobindo Pharma Ltd.
  • Alkem Laboratories
  • Abbott India

Quarterly Results

  • Aurobindo Pharma Ltd.
  • Alkem Laboratories
  • Abbott India

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Aurobindo Pharma Ltd. Financials

Balance sheet of Aurobindo Pharma is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Aurobindo Pharma is increasing.
Latest net debt of Aurobindo Pharma is -₹1,412.51 Crs as of Sep-25.
This is greater than Mar-25 when it was -₹8,529.09 Crs.

The profit is oscillating.
The profit of Aurobindo Pharma is ₹3,448 Crs for TTM, ₹3,486 Crs for Mar 2025 and ₹3,173 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Aurobindo Pharma latest dividend payout ratio is 8.31% and 3yr average dividend payout ratio is 8.71%

Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech